A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Centres for Medicare and Medicaid Services on Friday said that it did not move forward with a proposal put forward by the ...

April 4, that modernizes and improves Medicare Advantage (MA), Medicare Prescription Drug Benefit (Part D), Medicare cost ...

Many Britons hold the Fundsmith Equity fund in their Stocks and Shares ISAs. Is this still a good move? Edward Sheldon ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Here's everything you need to know about the new weight loss medication being rolled out by the NHS to treat obesity.